AzTrials
AzTrials

Fuchs' Corneal Endothelial Dystrophy (FCED)Phase 1/2SPIFD-101NCT02653391

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

A Phase 1/2 study testing Part A Elamipretide 1.0% Ophthalmic Solution and Part B Elamipretide 3.0% Ophthalmic Solution in people with Fuchs' Corneal Endothelial Dystrophy (FCED), run by Stealth BioTherapeutics Inc. at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Part A Elamipretide 1.0% Ophthalmic Solution and Part B Elamipretide 3.0% Ophthalmic Solution
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
22 participants
Where
2 sitesUnited States
Study dates
Feb 2016to Dec 2018
Phase
Phase 1/2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults ≥18 years old at the time of Screening Visit
  • Diagnosis of FCED OU (both eyes) based on clinical and ophthalmic test findings
  • Clinical evidence of corneal edema OU diagnosed with FCED, including one or more of the following signs: corneal epithelial microcysts, corneal epithelial bullae, stromal folds, or stromal haze
  • Central corneal thickness of 550 μm to 700 μm (inclusive) in at least one eye diagnosed with FCED, as measured by ultrasonic pachymetry at the time of Screening Visit and Baseline Visit
  • Best-corrected distance visual acuity (BCVA) of 20/25 to 20/320 (inclusive) at the time of Screening Visit and Baseline Visit OU
  • Women of childbearing potential must agree to use birth control as specified in the protocol from the date they sign the informed consent form (ICF) until after the last study
  • Able to give informed consent and willing to comply with all study visits and examinations
  • Part B only: The presence of central endothelium, as determined by the investigator, with an area of contiguous endothelial cells within 1 mm of the central cornea as measured by confocal laser scanning microscopy (CLSM) or specular microscopy at the time of Screening Visit

Who cannot join

  • Corneal findings of any type (including, but not limited to, stromal haze or stromal scarring), in either eye, that, based on investigator's assessment, limit the probability of visual improvement after corneal deturgescence
  • Any ocular pathology requiring treatment with topical ophthalmic drops, with the exception of glaucoma or ocular hypertension
  • Use of topical hypertonic saline drops for 3 days prior to Screening and throughout the duration of the study
  • History of corneal disease (other than FCED) or corneal surgery in either eye
  • Current use or likely need for the use of contact lens at any time during the study
  • History of previous corneal or anterior segment surgery such as LASIK, photorefractive keratectomy, endothelial keratoplasty, penetrating keratoplasty cataract surgery or glaucoma surgery.
Show all 11Show fewer
  • Any disease or medical condition that in the opinion of the investigator would prevent the subject from participating in the study or might confound study results
  • Participation in other investigational drug or device clinical trials within 30 days prior to enrollment, or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion
  • Women who are pregnant or lactating
  • Part B only: Participation in Part A of SPIFD-101
  • Other protocol-defined inclusion/exclusion criteria may apply.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114

  • Cincinnati Eye Institute

    Edgewood, Kentucky, 41017

Other trials in United States

About this study

Official title: Part A: a Prospective, Randomized, Double-masked, Vehicle Controlled, Paired-eye Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild to Moderate Corneal Edema Part B: a Prospective, Randomized, Double-masked, Vehicle Controlled, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With FCED Presenting With Mild to Moderate Corneal Edema.

This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema.

Read the detailed description

This is a Phase 1/2 trial in two parts. Part A is a prospective, randomized, double-masked, vehicle controlled, paired-eye study in approximately 16 subjects to evaluate safety, tolerability and efficacy of elamipretide 1.0% topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema. Part B is a prospective, randomized double-masked, vehicle controlled study in approximately 11 subjects to evaluate safety, tolerability, and efficacy of elamipretide 3.0% topical ophthalmic solution in patients with FCED presenting with mild to moderate corneal edema.

Being tested
Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
Keywords
Fuchs' Corneal Endothelial Dystrophy, FCED, Ocuvia™, MTP-131
Medical subject headings
Fuchs' Endothelial Dystrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Part A Elamipretide 1.0% Ophthalmic SolutionDrug

    Also called MTP-131, Bendavia

    Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.

  • Part B Elamipretide 3.0% Ophthalmic SolutionDrug

    Also called MTP-131, Bendavia

    Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.

  • Part A PlaceboDrug

    Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.

  • Part B PlaceboDrug

    Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.

Study groups in NCT02653391
Study groupRoleWhat they receive
Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)ExperimentalPart A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
Receives: Drug: Part A Elamipretide 1.0% Ophthalmic Solution
Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)ExperimentalPart B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
Receives: Drug: Part B Elamipretide 3.0% Ophthalmic Solution
Placebo APlacebo comparatorPart A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
Receives: Drug: Part A Placebo
Part B PlaceboPlacebo comparatorPart B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
Receives: Drug: Part B Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence and Severity of Ocular TEAEs.

    The incidence and severity of ocular treatment emergent adverse events (TEAEs)

    Measured: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16

  2. The Incidence and Severity of Systemic Adverse Events

    The incidence and severity of systemic treatment emergent adverse events (TEAEs)

    Measured: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16

  3. Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part A

    Number of participants who had a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part A. Part B is reported as separate outcome since unit of measure is number of eyes.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16

  4. Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part B

    Number of eyes with a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part B. Part A is reported as separate outcome.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16

  5. Change From Baseline in Intraocular Pressure (IOP) for Part A

    Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part A

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12

  6. Change From Baseline in Intraocular Pressure (IOP) for Part B

    Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part B. Part A is reported separately.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12 , and Week 16 or early discontinuation visit

Secondary outcomes (18)
  1. Change From Baseline in Central Corneal Thickness by Visit Part A as Measured by Pachymetry for Part A

    Change from Baseline in Central Corneal Thickness by Visit as measured by Pachymetry for Part A. Part B is reported as a separate outcome measure.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16

  2. Central Corneal Thickness Part B

    Central Corneal Thickness: by-subject data as measured by Pachymetry and Pentacam. Part A is reported as a separate outcome measure.

    Measured: Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16, or Early discontinuation visit

  3. Change From Baseline Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A

    Change From Baseline in Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A. Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium. Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells. Histologically, healthy corneal cells initially have a hexagonal shape. As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell. This, in turn, causes the remaining cells to lose their hexagonal shape. Assessments were performed using the flex center and full auto methods for Part A and data from the flex center method was summarized. The flex center method was used for Part B. The percent of Part B is entered as a separate outcome measure. A decrease from baseline in % cell hexagonality means worse outcome, a increase from baseline means better outcome.

    Measured: Baseline, Week 1, 4, 8, and 12

  4. Corneal Endothelial Cell Hexagonality Part B

    Corneal Endothelial Cell Hexagonality in Percentage by-subject data: Part B. Data was only listed in weeks where images were good enough quality to quantify. Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium. Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells. Histologically, healthy corneal cells initially have a hexagonal shape. As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell. This, in turn, causes the remaining cells to lose their hexagonal shape. The flex center method was used for Part B. A decrease in percent of cell hexagonality from baseline means worse outcome, an increase from baseline means better outcome.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16 or early discontinuation visit

  5. Change From Baseline in Best Corrected Visual Acuity (BCVA) Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale for Part A.

    Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome). Part B was listed separately.

    Measured: Baseline, Weeks 1, 4, 8, 12, and 16

  6. Best Corrected Visual Acuity (BCVA) Score Using ETDRS Scale for Part B

    Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

    Measured: Baseline, Weeks 1, 4, 8, 12, and 16

  7. Change From Baseline in Endothelial Cell Density Over All 12 Weeks for Part A

    Change From Baseline in Endothelial Cell Counts, or density (Counts/mm^2) over all 12 weeks for Part A. Part B is entered as a separate outcome measure.

    Measured: Baseline, Weeks 1, 4, 8, and 12

  8. Corneal Endothelial Cell Density Part B

    Corneal Endothelial Cell Density: Part B, By-subject data for all time points where images were readable. For all time points where there were "Poor Quality Images" or "too few cells to register", there were no data available, and these were not listed below.

    Measured: Baseline, Weeks 1, 4, 8, 12, and 16.

  9. Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks for Part A

    Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks. Coefficient of variation (CV) is Standard deviation (SD) of cell area divided by the mean cell area of endothelial cell analyzed. CV represents the coefficient, or degree, of variation in the sizes of the endothelial cells (polymegethism). By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring. The more variation, the worse the outcome. Part B is is entered as a separate outcome measure.

    Measured: Baseline, Week 12

  10. Coefficient of Variation (CoV) Part B

    Part B, By-subject data for all time points where images were readable. For all time points where there were "Poor Quality Images" or "too few cells to register" there were no data available. CoV represents the coefficient, or degree, of variation in the sizes of the endothelial cells. By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring. A CoV less than 40 is normal.

    Measured: Baseline, Weeks 1, 4, 8,12, and 16

  11. Change From Baseline in Corneal Area Affected by Microcysts for Part A

    Change from Baseline in corneal area affected by microcysts by visit for Part A.

    Measured: Baseline, Weeks 1, 4, 8, 12, and 16

  12. Corneal Area Affected by Microcysts: Part B

    Corneal area affected by microcysts: by-subject data for Part B. No microcysts were present for any timepoints.

    Measured: Baseline, Weeks 1, 4, 8, 12, and 16, or early discontinuation visit

  13. Change From Baseline in Corneal Bullae for Part A.

    Count of participants in number, size and location of bullae by treatment. Part B is listed separately.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16

  14. Corneal Bullae: Part B

    Number, size and location of Corneal bullae: By-subject data: Part B.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit

  15. Change From Baseline in Severity of Corneal Stromal Folds for Part A

    Change from baseline in severity of corneal stromal folds by visit. Descriptive assessment made by Investigator; severity is not assessed using a scale.

    Measured: Baseline, Weeks 1, 4, 8, 12, and 16

  16. Severity of Corneal Stromal Folds:Part B

    Severity of corneal stromal folds by-subject data by visit. Descriptive assessment made by Investigator in the following categories: Not present, trace, mild.

    Measured: Baseline, Week 1, 4, 8, 12, and 16, or early discontinuation visit

  17. Change From Baseline in Contrast Sensitivity (Log Score) for Part A

    Change from Baseline in contrast sensitivity over all 12 weeks log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E. Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values. Lower log scores equals lower contrast sensitivity and worse outcome. Higher log scores mean higher contrast sensitivity and better outcome. For 3cpd, range is 0.7-2.08; 6 cpd: 0.91-2.29; 12 cpd: 0.61-1.99; 18cpd: 0.17-1.55, unless no gratings were visible. If no gratings were visible, .3 log was subtracted from the lowest score for 3, 6, and 12cpd. For 18cpd .01 log was used, or essentially 100% contrast.

    Measured: Baseline, Week 1, 4, 8, 12 weeks

  18. Contrast Sensitivity for Part B; By-subject Data

    Contrast Sensitivity log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E by-subject data, Part B. Part A is listed separately. Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values. Lower log scores equals lower contrast sensitivity and worse outcome. Higher log scores mean higher contrast sensitivity and better outcome. For 3cpd, range is 0.7-2.08; 6 cpd: 0.91-2.29; 12 cpd: 0.61-1.99; 18cpd: 0.17-1.55, unless no gratings were visible. If no gratings were visible, .3 log was subtracted from the lowest score for 3, 6, and 12cpd. For 18cpd .01 log was used, or essentially 100% contrast.

    Measured: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2016 (estimated)
  2. Study startFeb 2016
  3. Primary completionMar 2018
  4. Study completionDec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
22 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02653391
Sponsor's protocol ID
SPIFD-101
Acronym
SPIFD-101
Status last verified
Aug 2021
First submitted
20 Dec 2015
Last updated
17 Sep 2021
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Part A Elamipretide 1.0% Ophthalmic Solution and Part B Elamipretide 3.0% Ophthalmic Solution in people with Fuchs' Corneal Endothelial Dystrophy (FCED), run by Stealth BioTherapeutics Inc. at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Sep 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence and Severity of Ocular TEAEs. (time frame: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in